Format

Send to

Choose Destination
Eur J Cancer. 2008 Nov;44(17):2542-5. doi: 10.1016/j.ejca.2008.08.014. Epub 2008 Sep 24.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

Author information

1
Department of Medical Oncology (452), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. C.vanHerpen@onco.umcn.nl

Abstract

BACKGROUND:

This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC).

PATIENTS AND METHODS:

Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m(2) intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles.

RESULTS:

Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients.

CONCLUSION:

We conclude that gemcitabine is not an active drug in ACC.

PMID:
18819792
DOI:
10.1016/j.ejca.2008.08.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center